The class, defined
Longevity peptides are short protein chains studied for their effects on cellular aging, mitochondrial function, senescent-cell clearance, telomere maintenance, and systemic inflammation — the hallmarks of aging defined by López-Otín and colleagues. Unlike the GLP-1 and recovery pillars, there is no FDA-approved longevity peptide as of 2026 for any age-related indication. The entire category sits in the research-chemical or bioregulator space, often sourced from Russian or Eastern European suppliers where some compounds (Epithalon, Cortagen, Cortexin) have been registered as locally-approved bioregulators for decades. This hub catalogs the eight direct longevity peptides PeptaHub profiles plus two cross-category peptides (Thymosin Alpha-1 from immune, GHK-Cu from skin) that are commonly used in longevity protocols. The category is where peptide evidence is thinnest and user enthusiasm is highest — a difficult combination that we navigate by being explicit about what's clinically supported versus what's preclinical or theoretical.
How they work
Longevity peptides target distinct hallmarks of aging: Epithalon and related bioregulators are proposed to activate telomerase and extend replicative lifespan; mitochondrial-derived peptides (MOTS-c, humanin, SHLP2) signal across the mitonuclear axis to improve metabolic flexibility; SS-31 (elamipretide) stabilizes the inner mitochondrial membrane via cardiolipin binding; FOXO4-DRI is a senolytic peptide that selectively induces apoptosis in senescent cells harboring elevated p53. Antioxidant peptides (carnosine, glutathione) quench reactive oxygen species and inhibit advanced glycation end-product formation. None of these mechanisms has been validated in a human randomized trial of longevity or healthspan endpoints — the evidence base is animal models, in vitro cell assays, and small observational human studies of surrogate biomarkers.
Telomere maintenance and bioregulators
Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson's group in the 1980s, proposed to activate telomerase and extend replicative lifespan in human cell lines. Preclinical data from the Khavinson program are encouraging; independent replication and Western clinical-trial evidence are limited. Pinealon, Cortagen, and Cortexin belong to the same bioregulator family and are positioned as organ-specific 'regulators' rather than conventional drugs.
Mitochondrial-derived peptides
MOTS-c is encoded in the mitochondrial 12S rRNA gene and acts as an AMPK activator, improving insulin sensitivity and muscle function in mouse models. Humanin is encoded in the mitochondrial 16S rRNA gene and has neuroprotective and cardioprotective effects. Both are part of the emerging 'mitochondrial-derived peptide' class — a paradigm shift in how we think about mitochondria as endocrine organs that signal to the nucleus.
Mitochondrial membrane stabilization
SS-31 (elamipretide) is a tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, preserving cristae structure and electron-transport-chain efficiency. Clinical trials for primary mitochondrial myopathy, heart failure, and Barth syndrome have produced mixed results — some endpoints met, others missed. The clearest human evidence of any longevity peptide on this list.
Senolytic peptides
FOXO4-DRI is a modified peptide that disrupts the interaction between FOXO4 and p53 in senescent cells, triggering apoptosis of senescent but not healthy cells. In preclinical models it reduces markers of cellular senescence and improves fur density, renal function, and physical performance in aged mice. No human trials as of 2026.
The complete list
10 peptides, ordered by clinical evidence tier. Each entry links to the full profile with mechanism, dosing, side effects, and legal-status detail.
Epithalon
Research (Russian bioregulator)Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Khavinson's pineal bioregulator program. Proposed to activate telomerase and extend replicative lifespan in human cell lines. Registered as a bioregulator in Russia; not FDA-approved in the US. The most recognizable longevity peptide and the category anchor.
MOTS-c
Research (mitochondrial)16-amino-acid mitochondrial-derived peptide encoded in the 12S rRNA gene. Activates AMPK, improves insulin sensitivity, and preserves skeletal-muscle function in aged mouse models. A prototype mitokine — one of the first validated signaling molecules secreted by mitochondria to regulate nuclear gene expression.
SS-31
Phase 2/3 (mitochondrial disease)Cardiolipin-binding tetrapeptide that preserves inner mitochondrial membrane structure. Phase 2/3 trials for primary mitochondrial myopathy, Barth syndrome, and heart failure have produced mixed results. The most clinically-developed peptide on this hub and the closest to an eventual FDA approval for an age-related indication.
FOXO4-DRI
Research (senolytic)D-retro-inverso peptide designed to disrupt FOXO4-p53 binding in senescent cells, selectively triggering their apoptosis. Improved physical function, fur density, and renal markers in aged mice. No human trials yet; the most advanced peptide-based senolytic in preclinical development.
Humanin
Research (mitochondrial)24-amino-acid peptide encoded in the mitochondrial 16S rRNA gene. Neuroprotective and cardioprotective effects in preclinical models. Declining circulating levels with aging correlate with metabolic dysfunction. Part of the mitokine paradigm alongside MOTS-c.
Ovagen
Research (bioregulator)Liver-targeted bioregulator peptide in the Khavinson family. Proposed to support hepatic regeneration and detoxification. Limited Western evidence; included for completeness of the Russian bioregulator class.
Carnosine
Supplement (oral)β-alanyl-L-histidine dipeptide, endogenous muscle and brain antioxidant. Inhibits protein glycation and advanced glycation end-product (AGE) formation. Available over-the-counter as an oral supplement; systemic bioavailability is limited by serum carnosinase. The most accessible longevity peptide.
Glutathione
Supplement / IV clinicTripeptide master antioxidant (γ-glutamyl-cysteinyl-glycine). Central to cellular redox homeostasis and phase-II detoxification. Declining with age and in many chronic conditions. Oral, liposomal, and IV formulations are widely available; clinical evidence is strong for oxidative-stress endpoints but weaker for lifespan or healthspan outcomes.
Thymosin Alpha-1
Approved (immune, cross-listed)28-amino-acid peptide approved for hepatitis B and C in multiple countries. Cross-listed here because of its role in reversing immunosenescence — the age-related decline in adaptive immune function. A rare example of an approved peptide with relevance to healthy-aging biology.
GHK-Cu
Cosmetic approved (skin cross-listed)Copper tripeptide cross-listed from skin and recovery for its cellular-repair and gene-modulation effects. Gene-expression studies show GHK-Cu resets 'young' transcriptional programs in aged fibroblasts. The most-studied peptide on this hub despite lacking longevity-specific trials.
Compared at a glance
Longevity peptides span a wider evidence gradient than any other pillar: from SS-31 with Phase 2/3 trials to FOXO4-DRI with only mouse data. The comparison below orders compounds by clinical development stage — SS-31 first (most advanced), mitochondrial-derived peptides next (strong preclinical), bioregulators third (clinical in Russia, research-only elsewhere), senolytics last (preclinical only). Users evaluating longevity peptides should read this ordering as a 'closest to validated' hierarchy, not a ranking of effectiveness.
| Peptide | Mechanism | Primary use | FDA status | Route | Half-life |
|---|---|---|---|---|---|
| SS-31 | Cardiolipin / mito membrane | Mitochondrial disease | Phase 2/3 | SC | ~2 hours |
| Thymosin Alpha-1 | T-cell / immune | Immunosenescence | Approved (EU) | SC | ~2 hours |
| MOTS-c | AMPK / mitokine | Metabolic healthspan | Research | SC | ~2 hours |
| Epithalon | Telomerase (proposed) | Pineal / telomere | Research (Russia) | SC | ~30 min |
| FOXO4-DRI | Senolytic / FOXO4-p53 | Senescent-cell clearance | Preclinical | IV (preclinical) | ~hours |
| Humanin | Mitokine / survival | Neuroprotection | Research | SC / endogenous | ~30 min |
SS-31 is the single longevity peptide with mature human clinical trials; Thymosin Alpha-1 is the only approved peptide with relevance to aging biology. Everything else on this hub is research-stage. Users seeking evidence-based longevity interventions should treat these compounds as hypothesis-generating rather than prescription-grade therapies.
Safety, side effects & legal status
Longevity peptides as a category have the thinnest safety database of any pillar. SS-31 has completed Phase 2/3 trials with a generally favorable safety profile; everything else relies on short-term preclinical toxicity data. The principal risks are supply-chain contamination (most longevity peptides are sourced from research-chemical vendors with inconsistent purity), long-term effects unknown by definition (a drug class aimed at extending lifespan is definitionally studied on short timescales), and theoretical oncogenic concerns — anything activating telomerase or suppressing senescence raises cancer-biology questions that haven't been adequately studied in humans. Carnosine and glutathione are sold as over-the-counter supplements with generally favorable safety profiles but limited efficacy data for longevity endpoints. Epithalon and other Russian bioregulators have decades of clinical use in Russia but little Western regulatory review. PeptaHub's approach: treat every longevity peptide as hypothesis-generating, not clinically-validated, and link every claim to the strongest available source.
How to think about this class
The longevity-peptide category sits at the intersection of two strong signals: genuine biological plausibility (the hallmarks of aging are real, and peptide-based interventions targeting them have compelling preclinical data) and genuine evidence thinness (no longevity peptide has a Phase 3 trial with a healthspan endpoint as of 2026). The rational posture is neither credulous (these peptides are proven to extend life) nor dismissive (these peptides are snake oil). They are hypothesis-generating interventions in an early research field. Eric Topol's skeptical 'Peptide Craze' essay and the BBC Science Focus survey of anti-aging peptides both provide useful counter-hype framing. The strongest candidates for near-term clinical validation are SS-31 (already in trials) and Thymosin Alpha-1 (already approved for other indications); everything else should be tracked, not adopted.
Frequently asked questions
A longevity peptide is a short protein chain studied for its effects on one or more hallmarks of aging — telomere maintenance, mitochondrial function, cellular senescence, stem-cell exhaustion, chronic inflammation, or proteostasis. There's no regulatory definition; the category is an informal grouping of compounds whose mechanism targets an aging-related process. Most longevity peptides on this hub are not primarily sold for longevity — they're studied for specific diseases (mitochondrial myopathy for SS-31, hepatitis for Thymosin Alpha-1) and repurposed conceptually for aging by a research community interested in healthspan extension.
No longevity peptide has been shown to extend human lifespan in a randomized controlled trial as of 2026 — because no such trial exists. Running a longevity RCT with a mortality endpoint requires decades of follow-up and is economically and logistically nearly impossible for a drug without an existing disease indication. The closest proxies are trials with surrogate aging biomarkers (epigenetic age, telomere length, inflammatory markers), none of which have reached Phase 3. Animal studies show lifespan extension for some compounds (Epithalon in mice, for instance), but animal-to-human translation for lifespan interventions has historically been poor.
Senolytics selectively kill senescent cells — cells that have permanently exited the cell cycle and accumulated with age, contributing to inflammation and tissue dysfunction. FOXO4-DRI is a peptide-based senolytic. Telomerase activators attempt to re-lengthen telomeres — the protective caps on chromosome ends that shorten with each cell division and eventually trigger senescence. Epithalon is proposed as a telomerase activator. Conceptually, they address aging from opposite ends: senolytics remove cells that have aged out, telomerase activators try to prevent cells from aging out in the first place. Both approaches have theoretical oncogenic risks that remain inadequately studied in humans.
Epithalon is sold in the US only as a 'research-only' chemical. It has no FDA approval for any indication and cannot legally be marketed or dispensed as a human medication. Vendors selling Epithalon with labeling claims for human use are violating federal drug laws regardless of the 'research-only' disclaimer. In Russia, Epithalon is registered as a bioregulator and has been used clinically for decades — that Russian registration does not extend to US legal status. Users considering Epithalon should understand they are acquiring an unapproved drug from an unregulated supply chain.
MOTS-c is distinctive because it's encoded in the mitochondrial genome rather than the nuclear genome — one of the first identified 'mitokines' (peptides secreted by mitochondria that signal to the rest of the cell). Its primary mechanism is AMPK activation, which mimics some of the metabolic effects of caloric restriction and exercise. MOTS-c levels decline with age in humans, and lower levels correlate with metabolic dysfunction. The conceptual novelty — that mitochondria are endocrine organs — is as interesting as the peptide itself.
Stacking longevity peptides is common in the self-experimentation community but has essentially no controlled-trial evidence. Theoretical rationales exist — combining a telomerase activator (Epithalon) with a senolytic (FOXO4-DRI) and a mitochondrial protector (SS-31) targets three different hallmarks of aging — but whether the combination produces additive, synergistic, or neutralizing effects is unknown. SS-31 has been studied alone in trials; none of its trials combined it with other longevity peptides. Users stacking multiple compounds should understand they are engaging in N-of-1 experiments without any expected outcome data.
There isn't one. The longevity research community is genuinely divided: some researchers (Khavinson's group, the mitokine discoverers, the Buck Institute senolytic program) view peptide-based longevity interventions as promising and clinically relevant. Others (Eric Topol, the BBC Science Focus consensus panel, many traditional gerontologists) view the field as overhyped with thin clinical evidence and excessive commercial promotion. Both camps agree that SS-31 and Thymosin Alpha-1 have the strongest human data; both agree that the weakest claims belong to the Russian bioregulators and the senolytics. PeptaHub's editorial position: treat longevity peptides as hypothesis-generating, not as validated therapies.
Sources & further reading
External citations underpinning this page. PeptaHub's full sourcing methodology is documented at /methodology — every claim on this page traces back to one of these references or a linked profile.
- Epitalon increases telomere length in human cell lines through telomerase upregulation — PMC
- AagingBase: comprehensive database of anti-aging peptides — Oxford Academic / Database
- AagingBase — NCBI mirror — PMC
- Most anti-ageing peptides don't work. But these might — BBC Science Focus
- The Peptide Craze (skeptical commentary) — Eric Topol — Substack
See also: glossary, FAQ, about PeptaHub.